Literature DB >> 3400100

Effects of calcium channel blockers on neurologic outcome after focal ischemia in rabbits.

P D Lyden1, J A Zivin, A Kochhar, V Mazzarella.   

Abstract

To determine the efficacy of calcium channel blockers in preserving neurologic function after central nervous system ischemia, we studied three such agents in two animal models. We treated rabbits after inducing ischemia in the brain with intra-arterial microspheres and in the spinal cord using a removable aortic occluding device. We found no benefit, in terms of neurologic functional outcome, from lidoflazine, nimodipine, or nicardipine. All three agents elevated regional blood flow in the spinal cord. We conclude that calcium antagonists are not likely to prove beneficial if used alone in the treatment of focal central nervous system ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3400100     DOI: 10.1161/01.str.19.8.1020

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat.

Authors:  P A Calle; M G Bogaert; L De Ridder; W A Buylaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

2.  The role of permeability to calcium in the formation of the level of local blood supply of the cerebral cortex.

Authors:  I A Gurbanov; G I D'yachuk; V F Maksimuk
Journal:  Neurosci Behav Physiol       Date:  1993 Nov-Dec

3.  Nimodipine has no effect on the cerebral circulation in conscious pigs, despite an increase in cardiac output.

Authors:  W J van der Giessen; D J Duncker; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

Review 4.  Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review.

Authors:  Neha Dhir; Bikash Medhi; Ajay Prakash; Manoj Kumar Goyal; Manish Modi; Sandeep Mohindra
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.